Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has earned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $21.40.

A number of brokerages recently issued reports on CLBT. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, DA Davidson began coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target for the company.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $13.05 on Tuesday. Cellebrite DI has a 1 year low of $11.02 and a 1 year high of $19.98. The stock has a market cap of $3.26 billion, a P/E ratio of 46.61, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. The firm has a 50-day moving average of $13.21 and a 200 day moving average of $15.01.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 13,269 shares of company stock valued at $169,592 over the last three months. 5.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its holdings in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after buying an additional 850 shares during the last quarter. Advisory Services Network LLC purchased a new position in Cellebrite DI in the third quarter worth about $40,000. CWM LLC raised its holdings in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after buying an additional 889 shares during the last quarter. First Horizon Corp raised its holdings in Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after buying an additional 2,337 shares during the last quarter. Finally, Vestcor Inc purchased a new position in Cellebrite DI in the third quarter worth about $70,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.